Takeda Pharma said that Rozerem is for the treatment of insomnia. It works by selectively targeting two melatonin receptors in the brain, MT1 and MT2. Earlier, in July 2005, Rozerem got FDA approval as the sleep medication.
Metact is a fixed dose combination tablet of Actos with Metformin and the first fixed dose combination for treatment of type 2 diabetes approved in Japan.
Actos OD tablets disintegrate in the oral cavity and can be taken easily without water. It is excepted that these drugs will enable the patients to avoid missing a dose due to the greater ease of administration and improve Adherence, thereby allowing patients with type 2 diabetes to better control their blood glucose levels.
Yasuhiko Yamanaka, senior vice president of pharmaceutical marketing division of Takeda, said: “The launch of Rozerem will mark our full-scale entry into the Japanese Central Nervous System market, one of our core therapeutic areas.
“Regarding diabetes, we expect that the addition of Metact and Actos OD tablets to our large line of products for treatment of diabetes will allow us to provide patients and healthcare professionals with better-tailored treatment options.”